Difference between revisions of "Pixantrone (Pixuvri)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
''Although this drug is EMA approved as of 5/31/2013, it is not yet FDA approved.'' | ''Although this drug is EMA approved as of 5/31/2013, it is not yet FDA approved.'' | ||
| + | |||
| + | ==Mechanism of action== | ||
| + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=269678 NCI Drug Dictionary]: The dimaleate salt of a synthetic, noncardiotoxic aza-anthracenedione analogue with potential antineoplastic activity. Pixantrone intercalates into DNA and induces topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity. | ||
| + | Route: IV | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[ | + | *[[Diffuse large B-cell lymphoma]] |
| + | |||
| + | ==Also known as== | ||
| + | BBR 2778, Pixantrone dimaleate | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| Line 11: | Line 18: | ||
[[Category:Aggressive Non-Hodgkin lymphoma medications]] | [[Category:Aggressive Non-Hodgkin lymphoma medications]] | ||
| − | [[Category: | + | [[Category:Drugs EMA approved in 2013]] |
Revision as of 01:25, 20 July 2017
Although this drug is EMA approved as of 5/31/2013, it is not yet FDA approved.
Mechanism of action
From the NCI Drug Dictionary: The dimaleate salt of a synthetic, noncardiotoxic aza-anthracenedione analogue with potential antineoplastic activity. Pixantrone intercalates into DNA and induces topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity. Route: IV
Diseases for which it is used
Also known as
BBR 2778, Pixantrone dimaleate